A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs MCS 110 (Primary) ; Carboplatin; Gemcitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 29 Sep 2017 Planned End Date changed from 6 Oct 2019 to 15 Jan 2019.
- 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Aug 2017 This trial has been suspended in Spain as per European Clinical Trials Database record